EMMPRIN and ADAM12 in prostate cancer: preliminary results of a prospective study
Extracellular metalloproteinase inducer (EMMPRIN) and a disintegrin and metalloproteinase (ADAM12) play a major role in cancer invasion and metastasis owing to the fact that they are directly related to the cell microenvironment and extracellular matrix (ECM) degradation. The aim of this study was to search for an answer to the question “whether the determination of EMMPRIN and ADAM12 values especially in urine may be helpful for the early diagnosis of prostate cancer without employing invasive methods” and also to check whether they may be useful for the determination of the patients with high metastasis risk. Peripheral blood and urine from 66 prostate cancer patients (40 local, 20 locally advanced, 6 metastatic) and 14 healthy controls were evaluated by enzyme-linked immunosorbent assay (ELISA) method. Serum EMMPRIN and ADAM12 values of the patients were seen to be statistically higher than the serum EMMPRIN and ADAM12 values of the healthy controls (p = 0.01 and p = 0.001, respectively). The urine ADAM12 levels were significantly higher in patients (p = 0.013). No significant relationships were found between urine EMMPRIN values of the patients and the healthy controls (p > 0.05). Positive correlation between urine EMMPRIN–urine ADAM12 tests was found in total patients group (r = 0.683, p = 0.001). Our preliminary results revealed that serum EMMPRIN and ADAM12 values and urine ADAM12 values may be useful markers in prostate cancer therapy. Due to the high correlation between these two tests, we are of the opinion that the use of urine ADAM12 in clinic may be sufficient and favorable together with prostate-specific antigen (PSA) for treatment.
KeywordsProstate Cancer Matrix metalloproteinase EMMPRIN ADAM12
The present work was supported by the Research Fund of Istanbul University, Project No. 18287.
Conflicts of interest
- 2.Aksun SA, Özmen D, Bayındır O. Metalloproteinazlar, inhibitörleri ve ilişkili fizyolojik ve patolojik durumlar. Turk Klin J Med Sci. 2001;21:332–42.Google Scholar
- 3.Reel B. Matriks metalloproteinaz enzimleri ve ateroskleroz. Turk Klin J Med Sci. 2006;26:527–37.Google Scholar
- 12.Wolfsberg TG, White JM. ADAM metalloproteases. In: Barrett AJ, Rawlings ND, Woessner JF, editors. Handbook of proteolytic enzymes. London: Academic; 2003. p. 1310–3.Google Scholar
- 14.Kumar RJ, Barqawi AB, Crawford ED. Epidemiology of prostate cancer. US Oncol Rev. 2005;1:1–6.Google Scholar
- 25.Bi XC, Liu JM, Zheng XG, Xian ZY, Feng ZW, Lou YX, et al. Over-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-specific antigen relapse after radical prostatectomy. Clin Invest Med. 2011;34:358.Google Scholar